The Company mainly engaged in the research and development of new stem cell drugs and the development of allogeneic mesenchymal stem cell technology platforms.
The Company s main product is the new stem cell drug product Stemchymal. The new stem cell drug product Stemchymal is used to treat spinocerebellar ataxia, Huntington s disease, acute ischemic stroke, acute inflammatory indications and other diseases.
HISTORY
The Company was established on December 18, 2007.
The Company was listed on PUBLIC COMPANIES on December 5, 2023.
The Company was listed on EMERGING STOCKS on March 11, 2024.
Headquarters
No.16,Wenhu St, Neihu Dist
Taipei City; Taipei City;
Contact Details: Purchase the Steminent Biotherapeutics Inc. report to view the information.
Website: http://www.steminent.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service